Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.

NCT Number	NCT07493447
Lead Sponsor	Eben Rosenthal
Conditions	Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Enrollment	30 participants
Start Date	2026-07
Primary Completion	2030-05 (estimated)
Study Completion	2031-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-30